Patients carrying CYP2C8*3 have shorter systemic paclitaxel exposure

AIM: First, evaluate if patients carrying putatively diminished activity CYP2C8 genotype have longer paclitaxel exposure (e.g., time above threshold concentration of 0.05 μM [T(c >0.05)]). Second, screen additional pharmacogenes for associations with T(c >0.05). METHODS: Pharmacogene panel gen...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Pharmacogenomics
Main Authors: Marcath, Lauren A, Kidwell, Kelley M, Robinson, Adam C, Vangipuram, Kiran, Burness, Monika L, Griggs, Jennifer J, Poznak, Catherine Van, Schott, Anne F, Hayes, Daniel F, Henry, Norah Lynn, Hertz, Daniel L
Formato: Artigo
Idioma:Inglês
Publicado: Future Medicine Ltd 2019
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6562943/
https://ncbi.nlm.nih.gov/pubmed/30520341
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/pgs-2018-0162
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares